Replies to post #108149 on Creative Medical Technology Holdings Inc (CELZ)

[gint1]

$CELZ....just da factss: CELZ...Updated update:

$CELZ…Recent Updates:

Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeutic Protein HGF-1

PHOENIX, Feb. 1, 2021 /PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings, Inc.

JAN 27, 2021, 07:45 ETCreative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy

JAN 21, 2021, 08:15 ETCreative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz® Through FDA

JAN 20, 2021, 08:15 ETLeading Urologist Doubles Down on CaverStem® Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men

JAN 19, 2021, 07:45 ETCreative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes

JAN 12, 2021, 08:15 ETCreative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy


JAN 06, 2021, 07:45 ETImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients

DEC 31, 2020, 07:45 ETCreative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy

DEC 29, 2020, 07:45 ETCreative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model

DEC 22, 2020, 07:45 ETCreative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity

DEC 16, 2020, 07:45 ETCreative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

DEC 10, 2020, 07:45 ETCreative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

SEP 29, 2020, 08:15 ETCreative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

SEP 08, 2020, 08:15 ETApplication of Immunotherapy to $7 Billion Lower Back Pain Market Patented by Creative Medical Technology Holdings